GeminIQ Website Logo

Viewing ABCL free

Subscribe for full history, 50+ metrics, screener, watchlist...

AbCellera Biologics Inc.

ABCL

Companies in Pharmaceutical Preparations

AbCellera Biologics Inc. (ABCL) — SEC Financial Statements & Analysis

AbCellera Biologics Inc. (ABCL) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
776283921595612714812452172180
Available For Sale Securities Debt Securities
428405413461446469516522574627613616
Restricted Cash
----------2525
Cash Cash Equivalents And Short Term Investments
505534496553605626643670698761--
Restricted Cash Current
25252525252525252525--
Other Assets Current
981111331179567434057567164
Assets Current
665728695742765751743772814872920931
Assets Noncurrent
Property Plant And Equipment Net
----------277260
Intangible Assets Net Excluding Goodwill
3738394041425386119120124127
Goodwill
484848484848484848484848
Investments In Affiliates Subsidiaries Associates …
656393908282847672666359
Other Assets Noncurrent
6952535762971341131059481113
Assets Noncurrent
643629661660579609650641649616593606
Assets
1,3071,3571,3561,4021,3441,3611,3931,4121,4631,4881,5121,537
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Other Accrued Liabilities
----------3652
Accounts Payable And Other Accrued Liabilities Cur…
40515350485554444350--
Business Combination Contingent Consideration Liab…
-00098202051505455
Accrued Royalties Current
----------33
Contract With Customer Liability Current
81416171914661119189
Liabilities Current
4764696775778070105119110119
Liabilities Noncurrent
Operating Lease Liability Noncurrent
1341371371376361666668717578
Contract With Customer Liability Noncurrent
--61214688981628
Government Assistance Liability Noncurrent
176174169168157150142124-96--
Deferred Income Tax Liabilities Net
-910101010132230313333
Other Liabilities Noncurrent
1151227266652
Business Combination Contingent Consideration Liab…
-----0445556
Liabilities Noncurrent
322326323328246228235231228217219223
Liabilities
369390392395321304315302333336329342
Stockholders Equity
Common Stock Value
817802794792790777773770765753748745
Additional Paid In Capital Common Stock
19719819318116916615514112812110996
Accumulated Other Comprehensive Income Loss Net Of…
-2-4-3-3-7-4-1-2-2-2-1-2
Retained Earnings Accumulated Deficit
-73-29-213771117151202239280327356
Stockholders Equity
9389679641,0071,0231,0561,0781,1111,1301,1521,1831,195
Liabilities And Stockholders Equity
1,3071,3571,3561,4021,3441,3611,3931,4121,4631,4881,5121,537
Common Stock No Par Value
000000000000
Common Stock Shares Issued
304301299296296296291291291291287287
Shares Outstanding
304301299296296296291291291291287287

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
20267.05%54.48%----------
20250.50%79.60%154.23%-1.42%11.79%33.49%-17.66%-20.97%-6.40%5.59%24.53%27.02%
2024-2.97%-26.73%-19.31%-10.18%-8.42%-4.56%4.15%3.46%20.42%-16.44%-17.12%-30.48%
2023----20.95%-28.26%-38.02%0.00%28.44%18.28%-11.30%-18.27%-27.87%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
14.05
11.32
10.10
11.07
10.15
9.81
9.34
10.96
7.76
7.33
8.34
7.83
Quick Ratio
14.05
11.32
10.10
11.07
10.15
9.81
9.34
10.96
7.76
7.33
8.34
7.83
Working Capital
617.30M
663.93M
626.34M
675.12M
689.58M
674.76M
663.32M
701.17M
709.07M
752.97M
809.28M
811.83M
Leverage & Debt
Debt to Equity
0.39
0.40
0.41
0.39
0.31
0.29
0.29
0.27
0.29
0.29
0.28
0.29
Debt Ratio
0.28
0.29
0.29
0.28
0.24
0.22
0.23
0.21
0.23
0.23
0.22
0.22
Efficiency & Turnover
Asset Turnover TTM
0.06
0.06
0.03
0.02
0.02
0.02
0.02
0.02
0.02
0.03
0.03
0.09
Per Share Metrics
Diluted EPS TTM
-0.47
-0.49
-0.57
-0.55
-0.56
-0.55
-0.60
-0.52
-0.50
-0.51
-0.45
-0.26
Free Cash Flow Per Share TTM
-0.62
-0.58
-0.51
-0.47
-0.48
-0.64
-0.67
-0.58
-0.44
-0.42
-0.24
-0.65
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Margin Metrics
Operating Profit Margin TTM
-267.60%
-288.98%
-739.68%
-847.64%
-1,395.40%
-1,091.69%
-934.61%
-814.70%
-634.94%
-623.82%
-414.63%
-80.11%
Net Profit Margin TTM
-181.74%
-194.88%
-486.02%
-503.92%
-726.26%
-564.83%
-533.33%
-463.79%
-410.48%
-385.00%
-256.28%
-50.91%
Growth Metrics
Net Revenue Growth (1Y)
242.68%
160.56%
7.16%
-0.54%
-35.41%
-24.17%
-34.59%
-77.23%
-80.23%
-92.17%
-91.65%
-71.38%
Net Income Growth (1Y)
-14.24%
-10.10%
-2.34%
8.07%
14.28%
11.24%
36.13%
107.42%
192.84%
-192.35%
-152.00%
-136.89%
EPS Growth (1Y)
-15.77%
-11.42%
-3.66%
6.51%
12.37%
9.29%
33.66%
103.68%
187.88%
-191.04%
-151.25%
-136.35%
Valuation Metrics
P/E TTM
-7.35
-6.98
-8.76
-6.18
-3.95
-5.30
-4.36
-5.68
-9.03
-11.28
-10.31
-25.25
P/B
1.13
1.06
1.56
1.02
0.65
0.82
0.71
0.78
1.17
1.43
1.13
1.56
P/S TTM
13.35
13.60
42.56
31.14
28.72
29.91
23.26
26.35
37.05
43.42
26.43
12.86
Market Cap
1.06B
1.02B
1.50B
1.02B
663.85M
862.38M
766.62M
870.88M
1.33B
1.65B
1.33B
1.87B
Enterprise Value
955.67M
868.07M
1.40B
906.45M
479.59M
681.05M
614.98M
697.57M
1.18B
1.49B
1.13B
1.66B
Calculated Values
Free Cash Flow TTM
-189.23M
-174.07M
-153.11M
-138.99M
-143.29M
-186.95M
-197.36M
-170.40M
-127.63M
-120.82M
-68.20M
-187.06M
Net Debt
-102.06M
-153.51M
-108.16M
-117.44M
-184.27M
-181.33M
-151.64M
-173.31M
-148.57M
-158.32M
-197.42M
-204.75M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-05-14Purchase
Owner: Montalbano, John S.
Title: -
Shares: 20,000
Price/Share: $4.77
Value: $95,400.00
Shares Owned: 241,000
Relationship: Director
Ownership: Direct
2026-02-27Purchase
Owner: Booth, Andrew
Title: Chief Financial Officer
Shares: 42,600
Price/Share: $3.42
Value: $145,692.00
Shares Owned: 195,600
Relationship: Officer
Ownership: Direct
2026-02-27Purchase
Owner: Thermopylae, Holdings Ltd…
Title: -
Shares: 38,000
Price/Share: $3.44
Value: $130,720.00
Shares Owned: 56,134,097
Relationship: TenPercentOwner
Ownership: Direct
2026-02-26Purchase
Owner: Thermopylae, Holdings Ltd…
Title: -
Shares: 177,457
Price/Share: $3.27
Value: $580,284.39
Shares Owned: 56,096,097
Relationship: TenPercentOwner
Ownership: Direct
2025-11-26Purchase
Owner: Montalbano, John S.
Title: -
Shares: 50,000
Price/Share: $3.57
Value: $178,500.00
Shares Owned: 221,000
Relationship: Director
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
39.77%
Inst. Shares: 120,534,903
Shares Outstanding: 303,074,605
2025-12-31
35.35%
Inst. Shares: 105,595,034
Shares Outstanding: 298,707,082
2025-09-30
34.28%
Inst. Shares: 102,467,605
Shares Outstanding: 298,875,174
2025-06-30
35.49%
Inst. Shares: 105,952,984
Shares Outstanding: 298,508,601
2025-03-31
41.36%
Inst. Shares: 123,118,783
Shares Outstanding: 297,692,663

Research Faster.
Invest Smarter.

AbCellera Biologics Inc. (ABCL) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 50+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.